Paclitaxel i.v. Plus Cisplatin i.p for NACT in Patients With Advanced Ovarian Cancer
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
To test the effect of intravenous paclitaxel plus intraperitoneal cisplatin for neo-adjuvant
chemotherapy in patients with advanced ovarian cancer, the investigators conducted a phase
III single arm clinical trial. Included patients will receive interval debulking surgery
after 2-6 cycles neoadjuvant chemotherapy based on the clinical judgment of the gynecologic
oncologist. Six cycles of chemotherapy will conducted after surgery. And the neoadjuvant
chemotherapy is as follows: paclitaxel 135 mg/m2 i.v. and cisplatin 75 mg/m2 i.p. on day 1.
The primary end point is optimal debulking rates. the investigators also will evaluate effect
on parameters of volume of ascites, tumor size, duration of surgery, hemorrhage,
hospitalizations and postoperative complication etc. After comparing with data published
online, the investigators will try to find out if paclitaxel i.v. plus cisplatin i.p. is a
superior neoadjuvant chemotherapy for advanced ovarian carcinoma.